Protagonist Therapeutics, Inc

(NASDAQ:PTGX)

Latest On Protagonist Therapeutics, Inc (PTGX):

Date/Time Type Description Signal Details
2023-05-26 01:04 ESTNewsProtagonist Therapeutics Sees Steady If Bumpy ProgressN/A
2023-05-24 20:54 ESTNewsProtagonist Therapeutics: All Quiet Heading Into An Important H2 2023N/A
2023-05-12 13:28 ESTNewsProtagonist Therapeutics and Janssen's collaboration shows promise for oral therapy for IL-23-mediated diseasesN/A
2023-05-05 17:50 ESTNewsProtagonist GAAP EPS of -$0.67 in-lineN/A
2023-04-05 11:14 ESTNewsProtagonist Therapeutics prices $100M offeringN/A
2023-04-04 19:17 ESTNewsProtagonist falls on $100M public offeringN/A
2023-03-16 06:46 ESTNewsProtagonist GAAP EPS of -$0.69 misses by $0.10N/A
2023-03-09 21:16 ESTNewsProtagonist Therapeutics: More Good News Likely To ComeN/A
2023-03-07 23:28 ESTNewsJohnson & Johnson, Protagonist succeed in mid-stage trial for psoriasis candidateN/A
2023-03-07 08:43 ESTNewsCDTX, PTGX and TAST among premarket gainersN/A
2022-11-08 17:47 ESTNewsProtagonist GAAP EPS of -$0.64 beats by $0.23N/A
2022-08-05 06:50 ESTNewsProtagonist GAAP EPS of -$0.84 beats by $0.10N/A
2022-06-15 13:34 ESTNewsProtagonist Therapeutics (PTGX) Presents At Jefferies Healthcare Conference - SlideshowN/A
2022-06-08 23:40 ESTNewsProtagonist: Too Many Red FlagsN/A
2022-06-01 03:40 ESTNewsProtagonist Therapeutics (PTGX) Presents at Digestive Disease Week (DDW) 2022N/A
2022-05-05 08:14 ESTNewsProtagonist GAAP EPS of -$0.43 beats by $0.20, revenue of $25.7M beats by $8.65MN/A
2022-04-26 17:35 ESTNewsProtagonist hits 52-week low as Street reacts to data for ulcerative colitis candidateN/A
2022-04-26 01:38 ESTNewsProtagonist falls on data from phase 2 study of PN-943 to treat ulcerative colitisN/A
2022-04-15 02:54 ESTNewsProtagonist down 22% after FDA plans to rescind Breakthrough Therapy designation for rusfertideN/A
2022-03-29 08:38 ESTNewsAsif Ali is the new finance chief at Protagonist TherapeuticsN/A
2022-02-28 17:25 ESTNewsProtagonist GAAP EPS of -$0.77 beats by $0.02, revenue of $8.62M beats by $4.62MN/A
2022-02-01 13:28 ESTNewsProtagonist Is Still Being Undervalued Like There's Real RiskN/A
2021-12-10 01:25 ESTNewsProtagonist Therapeutics (PTGX) Investor Presentation - SlideshowN/A
2021-12-02 23:48 ESTNewsProtagonist chooses candidate to advance into phase 2 in collaboration with JanssenN/A
2021-11-15 11:02 ESTNewsPhase 2a data supports Protagonist genetic liver disease drug rusfertideN/A
2021-10-12 11:34 ESTNewsJ.P. Morgan upgrades Protagonist to overweight following clinical hold removalN/A
2021-10-11 16:22 ESTNewsProtagonist gains nearly double after FDA removes clinical hold on rusfertide programN/A
2021-10-11 16:21 ESTNewsProtagonist price target raised at Northland following removal of clinical holdN/A
2021-10-06 15:26 ESTNewsPTGX is at high risk of performing badlyN/A
2021-09-30 21:08 ESTNewsProtagonist Therapeutics: How To Buy The DipN/A
2021-09-28 00:11 ESTNewsWarning: PTGX has been downgraded to Very BearishN/A
2021-09-25 08:13 ESTNewsBELLUS Health, Akoya Biosciences lead weekly healthcare gainers; Protagonist trailN/A
2021-09-22 04:02 ESTNewsProtagonist loses more than half after FDA placed clinical hold on rusfertide studiesN/A
2021-09-22 04:01 ESTNewsBELLUS Health, Akoya Biosciences lead weakly healthcare gainers; Protagonist trailN/A
2021-09-22 04:00 ESTNewsProtagonist extends slide as regulatory setback prompts downgrade at JP MorganN/A
2021-09-22 03:59 ESTNewsWarning: PTGX has been downgraded to Very Bearish.N/A
2021-08-10 10:13 ESTNewsProtagonist Therapeutics resolves contract dispute with Zealand PharmaN/A
2021-07-21 20:41 ESTNewsDosing underway in Protagonist Therapeutics' early-stage study of PN-232N/A
2021-07-21 20:32 ESTNewsProtagonist wins FDA Breakthrough Therapy Designation for blood cancer therapyN/A
2021-07-21 20:24 ESTNewsProtagonist climbs on positive effect in mid-stage study for rusfertide in polycythemia veraN/A
2021-07-21 20:23 ESTNewsBiogen could reach over $600/share: Goldman Sachs, CRISPR upgraded on follow-up data; more in today’s analyst actionN/A
2021-07-21 20:22 ESTNewsProtagonist Therapeutics slumps 7.5% on raising $100M via public offeringN/A
2021-07-21 20:22 ESTNewsRAPT, SIOX, ACHL and PTGX among after-hours moversN/A
2021-07-21 20:21 ESTNewsProtagonist Therapeutics secures $115M capital via equity raiseN/A
2021-07-21 20:16 ESTNewsProtagonist Therapeutics closes $132M capital raiseN/A
2021-05-05 01:39 ESTNewsProtagonist EPS beats by $0.03, beats on revenueN/A
2021-03-12 04:31 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 04:31 ESTAnalyst RatingThe Analyst Target Price has increased from $35.4 to $37.Buy
2021-03-11 12:47 ESTNewsProtagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-11 04:23 ESTEarnings EstimateAn EPS average of -$1.48 is estimated for the 2022 year.Sell

About Protagonist Therapeutics, Inc (PTGX):

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

PTGX Quotes by TradingView

See Advanced Chart

General

  • Name Protagonist Therapeutics, Inc
  • Symbol PTGX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 79
  • Fiscal Year EndDecember
  • IPO Date2016-08-11
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.protagonist-inc.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 37.31
  • Price/Book (Most Recent Quarter) 4.86
  • Enterprise Value Revenue 37.04
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.97
  • Next Year EPS Estimate -$2.12
  • Next Quarter EPS Estimate -$0.54
  • Profit Margin -231%
  • Operating Margin -225%
  • Return on Assets -17%
  • Return on Equity -37%
  • Revenue 28.63 million
  • Earnings Per Share -$2.74
  • Revenue Per Share $0.83
  • Gross Profit 28.63 million
  • Quarterly Earnings Growth 107.8%
View More

Highlights

  • Market Capitalization 1.36 billion
  • EBITDA -70271000
  • Analyst Target Price $37
  • Book Value Per Share $6.39
View More

Share Statistics

  • Shares Outstanding 43.81 million
  • Shares Float 27.88 million
  • % Held by Insiders 161%
  • % Held by Institutions 93.65%
  • Shares Short 2.77 million
  • Shares Short Prior Month 2.78 million
  • Short Ratio 8.34
  • Short % of Float 7%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • Beta 1.55
  • 52 Week High $31.58
  • 52 Week Low $5.44
  • 50 Day Moving Average 26.03
  • 200 Day Moving Average 22.63
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Protagonist Therapeutics, Inc (PTGX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Protagonist Therapeutics, Inc (PTGX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-10$5.65 million-$0.48-$0.48-0.61%
2020-09-302020-11-04$N/A-$0.21-$0.6165.71%
2020-06-302020-08-06$N/A-$0.59-$0.57-2.91%
2020-03-312020-05-07$3.65 million-$0.72-$0.69-4.05%
2019-12-312020-03-10$2.72 million-$0.63-$0.652.78%
2019-09-302019-11-06$4.14 million-$0.61-$0.7720.26%
2019-06-302019-08-07$-8189000-$1.18-$0.39-206.49%
2019-03-312019-05-08$1.56 million-$0.58-$0.56-4.5%
2018-12-312019-03-12$2.35 million-$0.57-$0.47-20.25%
2018-09-302018-11-06$6.12 million-$0.38-$0.37-1.79%
2018-06-302018-08-07$11.67 million-$0.41-$0.30-35.18%
2018-03-312018-05-09$10.78 million-$0.36-$0.24-50%
2017-12-312018-03-07$11.28 million-$0.15-$0.3455.88%
2017-09-302017-11-06$8.78 million-$0.29-$0.8163.98%
2017-06-302017-08-08$N/A-$0.89-$0.86-4.09%
2017-03-312017-05-10$N/A-$0.84-$0.67-26.32%
2016-12-312017-03-07$N/A-$0.67-$0.52-28.85%
2016-09-302016-11-14$N/A-$0.87-$0.64-35.94%
2016-06-302016-07-11$N/A-$40.89-$0.83-4826.51%

Protagonist Therapeutics, Inc (PTGX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 19.49 million N/A N/A 18.77 million 15.91 million
Income Before Tax -18.89 million N/A N/A -19.9 million -16.65 million
Selling General Administrative 4.99 million N/A N/A 4.58 million 4.11 million
Gross Profit N/A N/A N/A N/A 2.72 million
Ebit -18.76 million N/A N/A -19 million -17.3 million
Operating Income -18.83 million N/A N/A -19.7 million -17.3 million
Income Tax Expense N/A N/A 1.13 million 176000 856000
Total Revenue 5.65 million N/A N/A 3.65 million 2.72 million
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net -9000 N/A N/A -490000 654000
Net Income From Continuing Operations -18.89 million N/A N/A -20.08 million -17.5 million
Net Income Applicable to Common Shares -18.89 million -7.76 million -19.42 million -20.08 million -17.5 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A -32.35 million
Change to Liabilities -13.18 million -5.87 million -1.57 million N/A -4.06 million
Total Cash Flow from Investing Activities -54.12 million -5.17 million 42.73 million N/A -32.04 million
Net Borrowings N/A -10.52 million N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A N/A 25.24 million
Change to Operating Activities 1.85 million -590000 -679000 N/A 725000
Change in Cash N/A N/A N/A N/A -20.95 million
Total Cash from Operating Activities -16.29 million -21.48 million -15.85 million N/A -14.25 million
Depreciation N/A N/A N/A N/A 639000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A 2.94 million
Other Cash Flow from Financing Activities N/A -7000 -7000 N/A N/A
Change to Net Income 1.97 million 3.18 million 2.62 million N/A 1.91 million
Capital Expenditures N/A N/A N/A N/A -309000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 44.86 million N/A N/A 72.24 million N/A
Total Stockholder Equity 279.61 million N/A N/A 62.67 million N/A
Other Current Liabilities 15.94 million 18.84 million N/A N/A N/A
Total Assets 324.47 million N/A N/A 134.9 million N/A
Common Stock N/A N/A N/A N/A N/A
Other Current Assets 6.29 million 10000 N/A 10000 N/A
Retained Earnings -283.81 million -264.93 million -257.16 million -237.74 million N/A
Other Liabilities 121000 4.28 million 16.88 million 20.42 million N/A
Other Assets 450000 450000 450000 1.53 million N/A
Cash 117.36 million N/A N/A 60.22 million N/A
Total Current Liabilities 40.24 million 38.56 million N/A 36.37 million N/A
Other Stockholder Equity 28000 -88000 -208000 107000 N/A
Property, Plant & Equipment 1.46 million 6.69 million 7.06 million 7.38 million N/A
Total Current Assets 315.61 million 204.15 million N/A 125.99 million N/A
Long Term Investments 2 million N/A N/A N/A N/A
Net Tangible Assets 279.61 million 169.59 million 167.49 million 62.67 million N/A
Short Term Investments 188.45 million N/A N/A 57.3 million N/A
Long Term Debt N/A N/A N/A 9.83 million N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 24.31 million 2.8 million N/A 3.7 million N/A

Protagonist Therapeutics, Inc (PTGX) Chart:

Protagonist Therapeutics, Inc (PTGX) News:

Below you will find a list of latest news for Protagonist Therapeutics, Inc (PTGX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Protagonist Therapeutics, Inc (PTGX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-09-19300CALL0 0112.57TRUE00
2025-09-19350CALL0 0175.77TRUE00
2025-09-19400CALL0 0145.33TRUE00
2025-09-19450CALL0 0113.91TRUE00
2025-09-19500CALL0 037.92TRUE00
2025-09-19553.2CALL0 75031.85TRUE00
2025-09-19601.35CALL6 127636.66FALSE1.350
2025-09-19650.38CALL0 252.47FALSE00
2025-09-19700CALL0 0101.03FALSE00
2025-09-19750CALL0 0118.46FALSE00
2025-09-19800CALL0 0133.78FALSE00
2025-09-19300PUT0 0250.34FALSE00
2025-09-19350PUT0 0204.31FALSE00
2025-09-19400PUT0 0164.15FALSE00
2025-09-19450.8PUT0 16127.85FALSE00
2025-09-19500.8PUT0 355.55FALSE00
2025-09-19551.8PUT0 243.74FALSE00
2025-09-19600PUT0 045.9TRUE00
2025-09-19650PUT0 049.55TRUE00
2025-09-19700PUT0 061.35TRUE00
2025-09-19750PUT0 075.73TRUE00
2025-09-19800PUT0 082.7TRUE00
2025-10-17200CALL0 44228.68TRUE00
2025-10-1722.531.5CALL0 1224.11TRUE00
2025-10-17250CALL0 0202.06TRUE00
2025-10-17300CALL0 0161.74TRUE00
2025-10-17350CALL0 2133.16TRUE00
2025-10-174014.08CALL0 6109.93TRUE00
2025-10-174513.9CALL0 743.94TRUE00
2025-10-17508CALL0 2043.88TRUE00
2025-10-17554.57CALL0 3538.75TRUE00
2025-10-17602.4CALL0 23340.44FALSE00
2025-10-17650CALL0 1355.72FALSE00
2025-10-17700CALL0 370.13FALSE00
2025-10-17750CALL0 282.4FALSE00
2025-10-17800CALL0 093.16FALSE00
2025-10-17850CALL0 1102.78FALSE00
2025-10-17200PUT0 0263.01FALSE00
2025-10-1722.50PUT0 0237.21FALSE00
2025-10-17250PUT0 0214.57FALSE00
2025-10-17300PUT0 44176.07FALSE00
2025-10-17350PUT0 2143.82FALSE00
2025-10-17400PUT0 19115.69FALSE00
2025-10-17452.3PUT0 3090.28FALSE00
2025-10-17503.2PUT0 8559.86FALSE00
2025-10-17554.2PUT0 10742.77FALSE00
2025-10-17600PUT0 240.3TRUE00
2025-10-17650PUT0 041.85TRUE00
2025-10-17700PUT0 045.52TRUE00
2025-10-17750PUT0 046.45TRUE00
2025-10-17800PUT0 058.59TRUE00
2025-10-17850PUT0 066.62TRUE00
2026-01-1622.50CALL0 0128.88TRUE00
2026-01-16250CALL0 0119.91TRUE00
2026-01-16300CALL0 0100.3TRUE00
2026-01-16350CALL0 041.99TRUE00
2026-01-164017.35CALL0 9442.06TRUE00
2026-01-16450CALL0 044.62TRUE00
2026-01-16508.2CALL0 2641.13TRUE00
2026-01-16555.6CALL0 646.71TRUE00
2026-01-16604.87CALL0 1837.27FALSE00
2026-01-16650.95CALL0 136.91FALSE00
2026-01-16702.1CALL0 239.81FALSE00
2026-01-16751.15CALL0 337.06FALSE00
2026-01-16800.8CALL0 256.12FALSE00
2026-01-16850.75CALL0 162.07FALSE00
2026-01-1622.50PUT0 0146.87FALSE00
2026-01-16250.45PUT0 3132.95FALSE00
2026-01-16300.65PUT0 1109.3FALSE00
2026-01-16350.95PUT0 189.5FALSE00
2026-01-16401.5PUT0 172.25FALSE00
2026-01-16452.95PUT0 157.2FALSE00
2026-01-16506.6PUT0 5046.46FALSE00
2026-01-16550PUT0 041.64FALSE00
2026-01-16600PUT0 038.61TRUE00
2026-01-16650PUT0 040.54TRUE00
2026-01-16700PUT0 039.09TRUE00
2026-01-16750PUT0 041.65TRUE00
2026-01-16800PUT0 044.96TRUE00
2026-01-16850PUT0 046.55TRUE00
2026-03-2022.533CALL0 25105.48TRUE00
2026-03-202527.5CALL0 2694.27TRUE00
2026-03-20300CALL0 083.18TRUE00
2026-03-20350CALL0 036.98TRUE00
2026-03-20400CALL0 042.34TRUE00
2026-03-20459.3CALL0 245.33TRUE00
2026-03-205014.5CALL0 143.87TRUE00
2026-03-20557.5CALL0 1540.09TRUE00
2026-03-20600CALL0 038.34FALSE00
2026-03-20650CALL0 037.6FALSE00
2026-03-20700CALL0 037.63FALSE00
2026-03-20751.95CALL0 241.99FALSE00
2026-03-20801.35CALL0 650.31FALSE00
2026-03-20851.15CALL0 451.37FALSE00
2026-03-2022.50.5PUT0 1123.39FALSE00
2026-03-20250.8PUT0 1111.74FALSE00
2026-03-20300.8PUT0 191.96FALSE00
2026-03-20350PUT0 075.41FALSE00
2026-03-20400PUT0 061FALSE00
2026-03-20454.3PUT0 148.44FALSE00
2026-03-20500PUT0 043.46FALSE00
2026-03-20550PUT0 041.14FALSE00
2026-03-20600PUT0 040.5TRUE00
2026-03-206520.7PUT0 140.82TRUE00
2026-03-20700PUT0 039.41TRUE00
2026-03-20750PUT0 040.78TRUE00
2026-03-20800PUT0 042.15TRUE00
2026-03-20850PUT0 043.9TRUE00
2026-04-17300CALL0 051.94TRUE00
2026-04-17350CALL0 048.98TRUE00
2026-04-17400CALL0 044.22TRUE00
2026-04-17450CALL0 042.55TRUE00
2026-04-17500CALL0 041.21TRUE00
2026-04-17559.6CALL0 245.56TRUE00
2026-04-17600CALL0 038.58FALSE00
2026-04-17650CALL0 037.71FALSE00
2026-04-17700CALL0 036.83FALSE00
2026-04-17750CALL0 039.81FALSE00
2026-04-17801.75CALL0 143.47FALSE00
2026-04-17300PUT0 086.65FALSE00
2026-04-17350PUT0 071.1FALSE00
2026-04-17400PUT0 057.57FALSE00
2026-04-17450PUT0 046.19FALSE00
2026-04-17500PUT0 042.98FALSE00
2026-04-17550PUT0 041.91FALSE00
2026-04-17600PUT0 039.85TRUE00
2026-04-17650PUT0 038.86TRUE00
2026-04-17700PUT0 040.74TRUE00
2026-04-17750PUT0 040.84TRUE00
2026-04-17800PUT0 037.46TRUE00

Latest PTGX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST13$7.08
Jun 13, 2022 7:59 PM EST8$7.07
Jun 13, 2022 7:59 PM EST1$7.07
Jun 13, 2022 7:59 PM EST14$7.07
Jun 13, 2022 7:59 PM EST34$7.09

Protagonist Therapeutics, Inc (PTGX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000083423720009556/0000834237-20-009556-index.htm
2018-09-18UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1377121/000000000018029279/0000000000-18-029279-index.htm
2019-11-21UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1377121/000000000019015720/0000000000-19-015720-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000031506619001298/0000315066-19-001298-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000031506620001141/0000315066-20-001141-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000083423720008027/0000834237-20-008027-index.htm
2020-06-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000083423720009556/0000834237-20-009556-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000090266419000928/0000902664-19-000928-index.htm
2020-05-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000090266420002197/0000902664-20-002197-index.htm
2018-08-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000092189518002281/0000921895-18-002281-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000092189519000465/0000921895-19-000465-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000092189520000521/0000921895-20-000521-index.htm
2018-07-02SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000093041318002140/0000930413-18-002140-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000093041319000575/0000930413-19-000575-index.htm
2018-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746918005447/0001047469-18-005447-index.htm
2018-09-07S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1377121/000104746918006015/0001047469-18-006015-index.htm
2018-09-26424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1377121/000104746918006444/0001047469-18-006444-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1377121/000104746919002642/0001047469-19-002642-index.htm
2019-10-31S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1377121/000104746919006014/0001047469-19-006014-index.htm
2019-11-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746919006551/0001047469-19-006551-index.htm
2020-04-16DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1377121/000104746920002368/0001047469-20-002368-index.htm
2020-05-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746920002943/0001047469-20-002943-index.htm
2020-05-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1377121/000104746920003025/0001047469-20-003025-index.htm
2018-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918049635/0001104659-18-049635-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918049963/0001104659-18-049963-index.htm
2018-09-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1377121/000110465918057889/0001104659-18-057889-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918063178/0001104659-18-063178-index.htm
2018-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918066340/0001104659-18-066340-index.htm
2018-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918070107/0001104659-18-070107-index.htm
2018-12-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465918075322/0001104659-18-075322-index.htm
2019-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919014250/0001104659-19-014250-index.htm
2019-03-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1377121/000110465919014317/0001104659-19-014317-index.htm
2019-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919017130/0001104659-19-017130-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1377121/000110465919024116/0001104659-19-024116-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919027659/0001104659-19-027659-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919027662/0001104659-19-027662-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919029003/0001104659-19-029003-index.htm
2019-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919032445/0001104659-19-032445-index.htm
2019-06-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919035338/0001104659-19-035338-index.htm
2019-06-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000110465919035942/0001104659-19-035942-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919044426/0001104659-19-044426-index.htm
2019-10-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919058437/0001104659-19-058437-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919060537/0001104659-19-060537-index.htm
2019-11-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1377121/000110465919065981/0001104659-19-065981-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919068332/0001104659-19-068332-index.htm
2019-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465919069217/0001104659-19-069217-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000110465920021728/0001104659-20-021728-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920024253/0001104659-20-024253-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920031381/0001104659-20-031381-index.htm
2020-03-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1377121/000110465920031453/0001104659-20-031453-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920035420/0001104659-20-035420-index.htm
2020-04-16DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1377121/000110465920047714/0001104659-20-047714-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920058140/0001104659-20-058140-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920059922/0001104659-20-059922-index.htm
2020-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920067747/0001104659-20-067747-index.htm
2020-06-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1377121/000110465920070830/0001104659-20-070830-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920091424/0001104659-20-091424-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920094719/0001104659-20-094719-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920104437/0001104659-20-104437-index.htm
2020-10-028-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920111763/0001104659-20-111763-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000110465920121408/0001104659-20-121408-index.htm
2018-12-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312518345594/0001193125-18-345594-index.htm
2019-01-24SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312519015661/0001193125-19-015661-index.htm
2019-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312519028285/0001193125-19-028285-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312519040996/0001193125-19-040996-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000119312520038117/0001193125-20-038117-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118037316/0001209191-18-037316-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118037317/0001209191-18-037317-index.htm
2018-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118037318/0001209191-18-037318-index.htm
2018-07-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118042575/0001209191-18-042575-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047543/0001209191-18-047543-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047547/0001209191-18-047547-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047548/0001209191-18-047548-index.htm
2018-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919118047549/0001209191-18-047549-index.htm
2019-01-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003141/0001209191-19-003141-index.htm
2019-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003606/0001209191-19-003606-index.htm
2019-01-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003645/0001209191-19-003645-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119003994/0001209191-19-003994-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119008679/0001209191-19-008679-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015926/0001209191-19-015926-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015930/0001209191-19-015930-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119022776/0001209191-19-022776-index.htm
2019-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119022784/0001209191-19-022784-index.htm
2019-05-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119030616/0001209191-19-030616-index.htm
2019-06-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119034081/0001209191-19-034081-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119034082/0001209191-19-034082-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036195/0001209191-19-036195-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036203/0001209191-19-036203-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036204/0001209191-19-036204-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036207/0001209191-19-036207-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036211/0001209191-19-036211-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119036214/0001209191-19-036214-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119045195/0001209191-19-045195-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119045196/0001209191-19-045196-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058295/0001209191-19-058295-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058839/0001209191-19-058839-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919119058853/0001209191-19-058853-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014088/0001209191-20-014088-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014090/0001209191-20-014090-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014092/0001209191-20-014092-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014097/0001209191-20-014097-index.htm
2020-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120014100/0001209191-20-014100-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120018645/0001209191-20-018645-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120018752/0001209191-20-018752-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120020714/0001209191-20-020714-index.htm
2020-04-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120023949/0001209191-20-023949-index.htm
2020-05-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120026593/0001209191-20-026593-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033016/0001209191-20-033016-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033020/0001209191-20-033020-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033022/0001209191-20-033022-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033026/0001209191-20-033026-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033031/0001209191-20-033031-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120033032/0001209191-20-033032-index.htm
2020-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2020-08-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120047233/0001209191-20-047233-index.htm
2020-08-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1377121/000120919120047246/0001209191-20-047246-index.htm
2018-08-20SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000121465918005609/0001214659-18-005609-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000121465919001113/0001214659-19-001113-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000121465920001392/0001214659-20-001392-index.htm
2019-07-01SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000131924419000056/0001319244-19-000056-index.htm
2019-12-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000149315219019237/0001493152-19-019237-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1377121/000149315220002364/0001493152-20-002364-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1377121/000155837018006590/0001558370-18-006590-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837018006639/0001558370-18-006639-index.htm
2018-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837018008657/0001558370-18-008657-index.htm
2019-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1377121/000155837019001853/0001558370-19-001853-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837019004481/0001558370-19-004481-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837019007515/0001558370-19-007515-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837019010201/0001558370-19-010201-index.htm
2020-03-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1377121/000155837020002334/0001558370-20-002334-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837020005785/0001558370-20-005785-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837020009681/0001558370-20-009681-index.htm
2020-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1377121/000155837020012597/0001558370-20-012597-index.htm
2018-09-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1377121/999999999518002437/9999999995-18-002437-index.htm
2019-11-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1377121/999999999519002648/9999999995-19-002648-index.htm

Protagonist Therapeutics, Inc (PTGX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Protagonist Therapeutics, Inc (PTGX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 161%
Institutional Ownership: 9365%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-08-11CHAITAN PHD KHOSLADirectorSell2,499.0017.1942,952.060.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2019-12-03Donald A. KalkofenChief Financial OfficerBuy562.005.092,860.581,175.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2020-03-12HAROLD E SELICKDirectorBuy12,000.006.7080,400.0015,310.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120018645/0001209191-20-018645-index.htm
2019-02-28Suneel GuptaEVP Clinical OperationsBuy7,500.0017,500.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015926/0001209191-19-015926-index.htm
2019-02-06Richard S. ShamesChief Medical OfficerSell2,580.007.7119,891.8024,178.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2020-08-11CHAITAN PHD KHOSLADirectorBuy2,499.001.894,723.112,499.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120046427/0001209191-20-046427-index.htm
2019-02-28Samuel R SaksChief Development OfficerBuy2,500.002,500.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015930/0001209191-19-015930-index.htm
2019-02-06Richard S. ShamesChief Medical OfficerSell198.008.151,613.7026,758.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008675/0001209191-19-008675-index.htm
2018-08-15Richard S. ShamesChief Medical OfficerBuy18,750.0026,956.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047548/0001209191-18-047548-index.htm
2018-08-15Thomas P. O'NeilChief Financial OfficerBuy21,100.0030,560.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047549/0001209191-18-047549-index.htm
2019-03-01Richard S. ShamesChief Medical OfficerSell657.008.035,275.7132,021.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-02-28Richard S. ShamesChief Medical OfficerBuy8,500.0032,678.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015927/0001209191-19-015927-index.htm
2019-04-01HAROLD E SELICKDirectorBuy3,310.001.314,336.103,310.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119022784/0001209191-19-022784-index.htm
2018-08-15DINESH V PH D PATELPresident and CEOBuy82,050.00345,829.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047547/0001209191-18-047547-index.htm
2019-02-06DINESH V PH D PATELPresident and CEOSell10,132.007.7178,117.72357,264.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-02-06DINESH V PH D PATELPresident and CEOSell777.008.106,292.22367,396.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008690/0001209191-19-008690-index.htm
2019-01-11DINESH V PH D PATELPresident and CEOBuy22,344.001.1625,919.04368,173.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119003606/0001209191-19-003606-index.htm
2019-02-06David Y LiuChief Scientific OfficerSell3,821.007.7429,561.5537,007.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119008679/0001209191-19-008679-index.htm
2019-08-06DINESH V PH D PATELPresident and CEOSell10,792.008.8595,535.10374,792.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119045195/0001209191-19-045195-index.htm
2019-11-26DINESH V PH D PATELPresident and CEOBuy4,000.001.164,640.00379,824.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058295/0001209191-19-058295-index.htm
2019-03-01DINESH V PH D PATELPresident and CEOSell2,183.008.0317,529.49383,831.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-02-28DINESH V PH D PATELPresident and CEOBuy28,750.00386,014.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015935/0001209191-19-015935-index.htm
2019-12-03DINESH V PH D PATELPresident and CEOBuy10,000.005.5555,500.00389,824.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2018-08-15David Y LiuChief Scientific OfficerBuy25,800.0040,828.00https://www.sec.gov/Archives/edgar/data/1377121/000120919118047543/0001209191-18-047543-index.htm
2019-12-03DINESH V PH D PATELPresident and CEOBuy20,000.005.65113,000.00409,824.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058799/0001209191-19-058799-index.htm
2020-03-12DINESH V PH D PATELPresident and CEOBuy18,344.001.1621,279.04429,990.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120018752/0001209191-20-018752-index.htm
2020-03-20DINESH V PH D PATELPresident and CEOBuy10,000.001.8918,900.00439,990.00https://www.sec.gov/Archives/edgar/data/1377121/000120919120020714/0001209191-20-020714-index.htm
2019-12-03Suneel GuptaEVP Clinical OperationsBuy30,000.005.13153,900.0049,500.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058839/0001209191-19-058839-index.htm
2019-08-06David Y LiuChief Scientific OfficerSell3,395.008.8530,044.0549,802.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119045196/0001209191-19-045196-index.htm
2019-03-01David Y LiuChief Scientific OfficerSell810.008.036,504.3051,197.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-02-28David Y LiuChief Scientific OfficerBuy15,000.0052,007.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/0001209191-19-015939-index.htm
2019-12-03Donald A. KalkofenChief Financial OfficerBuy613.005.103,126.30613.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058800/0001209191-19-058800-index.htm
2019-12-03Bryan GiraudoDirectorBuy8,000.005.7045,620.008,000.00https://www.sec.gov/Archives/edgar/data/1377121/000120919119058853/0001209191-19-058853-index.htm